Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Allergic Rhinitis Drugs Market Forecast 2016-2026


News provided by

Visiongain Ltd

22 Sep, 2016, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, September 22, 2016 /PRNewswire/ --

Report Details  

What can be expected from the Allergic Rhinitis Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
 
Our 240-page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the allergic rhinitis drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Allergic Rhinitis Drugs submarkets:
• Intranasal Anthistamines
• Intranasal Corticosteroids
• Oral Antihistamines
• Immunotherapy and Vaccines

See detailed profiles or revenue forecasts for some the leading products in the market
How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the allergic rhinitis drugs market including:
• Patanase
• Astepro
• Astelin
• Dymista
• Nasonex
• Avamys
• Veramyst
• Flixonase
• Rhinocort
• Omnaris
• Nasacort
• Beconase
• Qnasl

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• Zetonna
• Allegra
• Zyrtec
• Claritin
• Xyzal
• Allelock
• Clarinex
• Ebastel
• Talion
• Staloral
• Alutard SQ
• Grazax
• Ragwitek

See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• EU5 - Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Allergic Rhinitis Drugs Market will reach $16,500m in 2026. We predict a high revenue growth over the forecast period driven by an urbanisation, climate change, increasing patient expectations and a higher incidence of allergic rhinitis symptoms, rapid growth of emerging economies and emerging allergic rhinitis drug technologies.

Our work analyses the key companies in the market. See visiongain's analysis of six leading companies, including these:
• GSK
• Merck & Co
• Sanofi
• Johnson & Johnson
• ALK-Abello
• UCB
• Kyowo Hako Kirin
• Stallergenes Greer

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Historic revenue, analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the allergic rhinitis drugs industry?
Our new report discusses issues and events affecting the allergic rhinitis drugs market. You will find discussions, including qualitative analyses:
• Highly competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations and invalidations of major drugs
• Launches of new drug categories

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co.
In summary, our 240-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Allergic Rhinitis Drugs market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket - discover prospects for leading allergic rhinitis drugs in the following areas: intranasal corticosteroids, intranasal antihistamines, oral antihistamines, and immunotherapy and vaccines.
• Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the allergic rhinitis drugs market - discover prospects for leading allergic rhinitis drugs: Patanase, Astepro, Astelin, Dymista, Nasonex, Avamys, Veramyst, Fixonase, Rhinocort, Omnaris, Nasacort, Beconase, Qnasl, Zetonna, Allegra, Zyrtec, Claritin, Xyzal, Allelock, Clarinex, Ebastel, Talion, Staloral, Alutard SQ, Grazax, Ragwitek.
• Revenue forecasts to 2026 for eleven leading national markets and one leading regional markets - US, EU5, China, Japan, India, Russia, and Brazil.
• Assessment of eight leading companies - analysis of products, revenue, mergers & acquisitions, product type and product pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the over the counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1726/Allergic-Rhinitis-Drugs-Market-Forecast-2016-2026

Companies Mentioned in this Report 

ActoGeniX

Adamis Pharmaceuticals

ALK- Abelló

Allergy Medical UK

Allergy Therapeutics

Almirall

Altana Pharma (Nycomed)

Anergis

Apotex

AstraZeneca

Atopix Therapeutics

Barr Laboratories

Bausch & Lomb

Belcher Pharmaceuticals

Biotech Tools

Catalent Pharma Solutions

Celsus Therapeutics

Dainippon Sumitomo

DBV Technologies

Dr Reddy's Laboratories

Eddingpharm

Eleventa

Genzyme (Sanofi)

GlaxoSmithKline

Greer Laboratories

Hisamitsu Pharmaceutical Co

Hoechst AG

Human Genome Sciences

Intas Pharmaceuticals

Johnson & Johnson

Keldman Healthcare

Kyowa Hakko Kirin

Leti Pharma (Laboratorios Leti)

Lupin Pharmaceuticals

Meda Pharma

Medpointe Inc (Meda Pharma)

Merck & Co

Mitsubishi Tanabe Pharma

Mylan

Nippon Paper Group

Novartis

Omega Pharma

Perrigo

Pfizer

ProStrakan (Kyowa Hakko Kirin)

Reckitt Benckiser

Roxane Laboratories (Boehringer Ingelheim)

Sanofi

Schering-Plough (Merck)

Shionogi & Co Ltd

Stallergenes

Sun Pharmaceuticals

Sunovion Pharmaceuticals (Dainippon Sumitomo)

Takeda

Teva Pharmaceuticals

Trimel Pharmaceuticals

Ube Industries

UCB

ViiV Healthcare

Wockhardt

Ziarco Pharma

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.